Pluristem Therapeutics PSTI today announced that the Company has issued a letter to shareholders that provides an overview of the numerous milestones recently achieved by the company. The letter can be found on the company's website. Highlights include:
Raised net $34 million in a secondary offering, bringing the company's cash position to approximately $70 million, with no debt
Targeting future clinical trials in Bone Marrow Transplant failure indications, following the improvement of clinical condition and hematological counts after treatment of critically ill patients under a compassionate use program at the Hadassah Medical Center in Jerusalem
Began FDA-approved Phase II clinical trials in the U.S. for Intermittent Claudication
Received approval for Phase I/II clinical trial in muscle injury in Germany
Received approval from the Indian Ministry of Health to begin Phase II clinical trials in Buerger's Disease patients
Filed for Orphan Drug Status with the U.S. FDA for Aplastic Anemia
Optimizing manufacturing processes for commercial scale up
Building a new state-of-the-art manufacturing GMP facility in Israel suitable for large-scale production.
Pursuing new indications and fields of research in lung disease and acute radiation syndrome
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in